The role of the endocannabinoid system in eating disorders: Pharmacological implications

Behavioural Pharmacology

Volumn 23, Issue 5-6, 2012, Pages 526-536

  Marco, Eva M ^a   Romero Zerbo, Silvana Y ^b,c   Viveros, María Paz ^a   Bermudez Silva, Francisco J ^b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c Endocrinology and Nutrition Clinical Unit   (Spain)

Author keywords

Anandamide; anorexia nervosa; binge eating; bulimia nervosa; CB1R; endocannabinoid based therapy; endocannabinoids

Indexed keywords

DIAZEPAM; DRONABINOL; ENDOCANNABINOID; GHRELIN; LEPTIN; NABILONE; NABIXIMOLS; RIMONABANT;

ANOREXIA NERVOSA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BINGE EATING DISORDER; BULIMIA; CACHEXIA; CANCER PAIN; DEPRESSION; DIET RESTRICTION; DISEASE MODEL; EATING DISORDER; ENERGY BALANCE; ENERGY EXPENDITURE; EXERCISE; FEEDING BEHAVIOR; FOOD ADDICTION; FOOD INTAKE; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; MORTALITY; MULTIPLE SCLEROSIS; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRADER WILLI SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPASTICITY; TUBE FEEDING; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANIMALS; APPETITE REGULATION; APPETITE STIMULANTS; ARCUATE NUCLEUS; CANNABINOID RECEPTOR ANTAGONISTS; DRUG INVERSE AGONISM; EATING DISORDERS; ENDOCANNABINOIDS; ENERGY METABOLISM; HUMANS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; POLYMORPHISM, GENETIC; RECEPTORS, CANNABINOID; SYNAPTIC TRANSMISSION;

EID: 84864873109     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328356c3c9     Document Type: Review

References (114)

1. American Psychiatric Association (1994). Diagnostic and Statistical manual of mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association.
2. Andre A, Gonthier MP (2010). The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol 42:1788-1801.
3. Baker D, Pryce G, DaviesWL, Hiley CR (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27:1-4.
4. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. (1995). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89-97.
5. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F (2010). The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 95:375-382.
6. Bermudez-Silva FJ, Cardinal P, Cota D (2012). The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 26:114-124.
7. Berry EM (2006). Pilot study of THC (2.5 mg2) in 9 ambulatory AN patients. The sixth Nordic congress on eating disorders; 13-15 September 2006; Aarhus, Denmark.
8. Biederman J, Ball SW, Monuteaux MC, Surman CB, Johnson JL, Zeitlin S (2007). Are girls with ADHD at risk for eating disorderSResults from a controlled, five-year prospective study. J Dev Behav Pediatr 28:302-307.
9. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463-468.
10. Blankman JL, Simon GM, Cravatt BF (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347-1356.
11. Blundell JE (1984). Serotonin and appetite. Neuropharmacology 23:1537-1551.
12. Bulik CM, Sullivan PF, Kendler KS (1998). Heritability of binge-eating and broadly defined bulimia nervosa. Biol Psychiatry 44:1210-1218.
13. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ (2004). Expression of cannabinoid CB1R by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24:2708-2715.
14. Cassin SE, von Ranson KM (2007). Is binge eating experienced as an addiction? Appetite 49:687-690.
15. Chiang KP, Gerber AL, Sipe JC, Cravatt BF (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 15:2113-2119.
16. Cone RD (2005). Anatomy and regulation of the central melanocortin system. Nat Neurosci 8:571-578.
17. Cota D (2007). CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23:507-517.
18. Cota D, Proulx K, Seeley RJ (2007). The role of CNS fuel sensing in energy and glucose regulation. Gastroenterology 132:2158-2168.
19. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fattyacid amides. Nature 384:83-87.
20. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, et al. (2002). Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med 8:643-644.
21. De Kloet AD, Woods SC (2009). Minireview: endocannabinoids and their receptors as targets for obesity therapy. Endocrinology 150:2531-2536.
22. DelParigi A, Tschöp M, Heiman ML, Salbe AD, Vozarova B, Sell SM, et al. (2002). High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 87:5461-5464.
23. De Petrocellis L, Di Marzo V (2010). Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 5:103-121.
24. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
25. Di Marzo V (2008a). Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 160:1-24.
26. Di Marzo V (2008b). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438-455.
27. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. (2001). Leptinregulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825.
28. Di Marzo V, Ligresti A, Cristino L (2009). The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes (Lond) 33 (Suppl 2):S18-S24.
29. DiPatrizio NV, Simansky KJ (2008). Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 28:9702-9709.
30. DiPatrizio NV, Astarita G, Schwartz G, Li X, Piomelli D (2011). Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA 108:12904-12908.
31. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB (1998). Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54:180-188.
32. Farrimond JA, Whalley BJ, Williams CM (2012). Non-delta tetrahydrocannabinol phytocannabinoids stimulate feeding in rats. Behav Pharmacol 23:113-117.
33. Foltin RW, Brady JV, Fischman MW (1986). Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25:577-582.
34. Frank GK,Wagner A, Achenbach S, McConaha C, Skovira K, Aizenstein H, et al. (2006). Altered brain activity in women recovered from bulimic-type eating disorders after a glucose challenge: a pilot study. Int J Eat Disord 39:76-79.
35. Frieling H, Albrecht H, Jedtberg S, Gozner A, Lenz B, Wilhelm J, et al. (2009). Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. Psychoneuroendocrinology 34:620-624.
36. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, et al. (2003). Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90-93.
37. Gaetani S, Kaye WH, Cuomo V, Piomelli D (2008). Role of endocannabinoids and their analogues in obesity and eating disorders. Eat Weight Disord 13:e42-e48.
38. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
39. Gatta-Cherifi B, Matias I, Vallée M, Tabarin A, Marsicano G, Piazza PV, et al. (2012). Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int J Obes (Lond) 36:880-885.
40. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C, et al. (2007). Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes (Lond) 31:908-912.
41. Gearhardt AN, Corbin WR, Brownell KD (2009). Preliminary validation of the Yale Food Addiction Scale. Appetite 52:430-436.
42. Gearhardt AN,White MA, Masheb RM, Morgan PT, Crosby RD, Grilo CM (2012). An examination of the food addiction construct in obese patients with binge eating disorder. Int J Eat Disord 45:657-663.
43. Gérard N, Pieters G, Goffin K, Bormans G, Van Laere K (2011). Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry 70: 777-784.
44. Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, et al. (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617.
45. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, et al. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071:10-23.
46. Gross H, Ebert MH, Faden VB, Goldberg SC, Kaye WH, Caine ED, et al. (1983). A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol 3:165-171.
47. Haj-Dahmane S, Shen RY (2005). The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J Neurosci 25:896-905.
48. Hentges ST, Low MJ,Williams JT (2005). Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J Neurosci 25:9746-9751.
49. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
50. Holtkamp K, Herpertz-Dahlmann B, Hebebrand K, Mika C, Kratzsch J, Hebebrand J (2006). Physical activity and restlessness correlate with leptin levels in patients with adolescent anorexia nervosa. Biol Psychiatry 60:311-313.
51. Ishiguro H, Carpio O, Horiuchi Y, Shu A, Higuchi S, Schanz N, et al. (2010). A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands. Synapse 64:92-96.
52. Jimerson DC, Wolfe BE, Metzger ED, Finkelstein DM, Cooper TB, Levine JM (1997). Decreased serotonin function in bulimia nervosa. Arch Gen Psychiatry 54:529-534.
53. Jimerson DC, Mantzoros C, Wolfe BE, Metzger ED (2000). Decreased serum leptin in bulimia nervosa. J Clin Endocrinol Metab 85:4511-4514.
54. Kaczocha M, Glaser ST, Chae J, Brown DA, Deutsch DG (2010). Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J Biol Chem 285:2796-2806.
55. Kaye W (2008). Neurobiology of anorexia and bulimia nervosa. Physiol Behav 94:121-135.
56. Kaye W, Strober M, Jimerson D (2004). The neurobiology of eating disorders. In: Charney DS, Nestler EJ, editors. The neurobiology of mental illness. New York: Oxford Press. pp. 1112-1128.
57. Kaye WH, Nagata T,Weltzin TE, Hsu LK, Sokol MS, McConaha C, et al. (2001). Double-blind placebo-controlled administration of fluoxetine in restrictingand restricting-purging-type anorexia nervosa. Biol Psychiatry 49:644-652.
58. Keimpema E, Mackie K, Harkany T (2011). Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci 32:551-561.
59. Kim SF (2012). Animal models of eating disorders. Neuroscience 211:2-12.
60. Kirkham TC,Williams CM, Fezza F, Di Marzo V (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557.
61. Klump KL, Miller KB, Keel PK, McGue M, Iacono WG (2001). Genetic and environmental influences on anorexia nervosa syndromes in a populationbased twin sample. Psychol Med 31:737-740.
62. Kozak KR, Crews BC, Morrow JD,Wang LH, Ma YH,Weinander R, et al. (2002). Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277:44877-44885.
63. Lewis DY, Brett RR (2010). Activity-based anorexia in C57/BL6 mice: effects of the phytocannabinoid, delta-9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2. Eur Neuropsychopharmacol 20:622-631.
64. Liu QR, Pan CH, Hishimoto A, Li CY, Xi ZX, Llorente-Berzal A, et al. (2009). Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav 8:519-530.
65. Lowe B, Zipfel S, Buchholz C, Dupont Y, Reas DL, Herzog W (2001). Long-term outcome of anorexia nervosa in a prospective 21-year follow-up study. Psychol Med 31:881-890.
66. Lu XY, Kim CS, Frazer A, Zhang W (2006). Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA 103:1593-1598.
67. Lucki I (1998). The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44:151-162.
68. Lutter M, Nestler EJ (2009). Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr 139:629-632.
69. Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky SA, Anderson JG, Jung S, et al. (2008). The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 11:752-753.
70. Maccarrone M, Gasperi V, Catani MV, Diep TA, Dainese E, Hansen HS, et al. (2010). The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr 30:423-440.
71. Mackie K (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. In: Pertwee RG, editor. Cannabinoids Handbook of experimental pharmacology. Vol. 168: Berlin: Springer. pp. 299-323.
72. Mahler SV, Smith KS, Berridge KC (2007). Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 32:2267-2278.
73. Maldonado R, Valverde O, Berrendero F (2006). Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225-232.
74. Matias I, Di Marzo V (2007). Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18:27-37.
75. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
76. Merlo LJ, Klingman C, Malasanos TH, Silverstein JH (2009). Exploration of food addiction in pediatric patients: a preliminary investigation. J Addict Med 3:26-32.
77. Meule A (2011). How Prevalent is 'Food Addiction'? Front Psychiatry 2:61.
78. Monteleone P, Di Lieto A, Tortorella A, Longobardi N, Maj M (2000). Circulating leptin in patients with anorexia nervosa, bulimia nervosa or binge-eating disorder: relationship to body weight, eating patterns, psychopathology and endocrine changes. Psychiatry Res 94:121-129.
79. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V (2005). Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30:1216-1221.
80. Monteleone P, Tortorella A, Martiadis V, Di Filippo C, Canestrelli B, Maj M (2008). The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women. Psychoneuroendocrinology 33:546-550.
81. Monteleone P, Bifulco M, Di Filippo C, Gazzerro P, Canestrelli B, Monteleone F, et al. (2009). Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. Genes Brain Behav 8:728-732.
82. Morrison CD, Berthoud HR (2007). Neurobiology of nutrition and obesity. Nutr Rev 65:517-534.
83. Muller TD, Reichwald K, Bronner G, Kirschner J, Nguyen TT, Scherag A, et al. (2008). Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. Child Adolesc Psychiatry Ment Health 2:33.
84. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
85. Naruse T, Amano H, Koizumi Y (1991). Possible involvement of dopamine D-1 and D-2 receptors in diazepam-induced hyperphagia in rats. Fundam Clin Pharmacol 5:677-693.
86. Nelson K, Walsh D, Deeter P, Sheehan F (1994). A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10:14-18.
87. O'Sullivan SE, Kendall DA (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215:611-616.
88. Okamoto Y, Tsuboi K, Ueda N (2009). Enzymatic formation of anandamide. Vitam Horm 81:1-24.
89. Onaivi ES (2006). Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54:231-246.
90. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100.
91. Peñ as-Lledó EM, Loeb KL, Martin L, Fan J (2007). Anterior cingulate activity in bulimia nervosa: a fMRI case study. Eat Weight Disord 12:e78-e82.
92. Pirke KM, Broocks A,Wilckens T, Marquard R, Schweiger U (1993). Starvationinduced hyperactivity in the rat: the role of endocrine and neurotransmitter changes. Neurosci Biobehav Rev 17:287-294.
93. Reyes-Rodríguez ML, Von Holle A, Ulman TF, Thornton LM, Klump KL, Brandt H, et al (2011). Posttraumatic stress disorder in anorexia nervosa. Psychosom Med 73: 491-497.
94. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, et al. (2006). Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 126:177-187.
95. Siegfried Z, Kanyas K, Latzer Y, Karni O, Bloch M, Lerer B, et al. (2004). Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am J Med Genet B Neuropsychiatr Genet 125B:126-130.
96. Simon GM, Cravatt BF (2008). Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283:9341-9349.
97. Sipe JC, Waalen J, Gerber A, Beutler E (2005). Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 29:755-759.
98. Starowicz K, Nigam S, Di Marzo V (2007). Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114:13-33.
99. Stoving RK, Andries A, Brixen K, Flyvbjerg A, Horder K, Frystyk J (2009). Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa. J Psychiatr Res 43:671-679.
100. Strober M, Schmidt-Lackner S, Freeman R, Bower S, Lampert C, DeAntonio M (1995). Recovery and relapse in adolescents with bipolar affective illness: a five-year naturalistic, prospective follow-up. J Am Acad Child Adolesc Psychiatry 34:724-731.
101. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97.
102. Tasker JG (2006). Rapid glucocorticoid actions in the hypothalamus as a mechanism of homeostatic integration. Obesity (Silver Spring) 14:259S-265S.
103. Troisi A, Di Lorenzo G, Lega I, Tesauro M, Bertoli A, Leo R, et al. (2005). Plasma ghrelin in anorexia, bulimia, and binge-eating disorder: relations with eating patterns and circulating concentrations of cortisol and thyroid hormones. Neuroendocrinology 81:259-266.
104. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N (2005). Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280:11082-11092.
105. Van der Stelt M, Di Marzo V (2003). The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133-150.
106. Van Kuyck K, Gé rard N, Van Laere K, Casteels C, Pieters G, Gabrië ls L, et al. (2009). Towards a neurocircuitry in anorexia nervosa: evidence from functional neuroimaging studies. J Psychiatr Res 43:1133-1145.
107. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329-332.
108. Verty AN, Evetts MJ, Crouch GJ, McGregor IS, Stefanidis A, Oldfield BJ (2011). The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. Neuropsychopharmacology 36:1349-1358.
109. Volkow ND, Wise RA (2005). How can drug addiction help us understand obesity? Nat Neurosci 8:555-560.
110. Volkow ND,Wang GJ, Fowler JS, Telang F (2008). Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos Trans R Soc Lond B Biol Sci 363:3191-3200.
111. Walker A (1994). Thesaurus of psychological index terms. Washintong, DC: American psychological Association.
112. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, et al. (2006). Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 295:2605-2612.
113. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, et al. (2004). Human cannabinoid receptor 1: 50 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 9:916-931.
114. Zigman JM, Elmquist JK (2003). Minireview: from anorexia to obesity-the yin and yang of body weight control. Endocrinology 144:3749-3756.